Baxter Emerges as Frontrunner in Gland Pharma Buy

May 12, 2016

Economic Times

U.S.-based Baxter has emerged as the frontrunner to buy unlisted Indian drugmaker, Gland Pharma.

Gland Pharma, based in the southern Indian city of Hyderabad, is a leading contract manufacturer of injectables -- supplying to drugmakers in the U.S. and India.

Several suitors have been named, including Torrent Pharma, PE buyout fund Advent, Perrigo and Dr Reddy's. Two companies reportedly submitted bids -- Baxter and China's Fosun Group, valuing Gland around $1.1 to $1.2 billion. 

Read the ET coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments